E-Qure competitorsClear all

E-Qure's top competitors include Elanix Biotechnologies, Qool Therapeutics, Obalon Therapeutics and Respicardia.
E-Qure
E-Qure
E-QURE developed a non-invasive, electrical stimulation (ES), medical device that cures Hard-to-Heal wounds and Ulcers.
Elanix Biotechnologies
Elanix Biotechnologies
Elanix Biotechnologies develops and commercializes products for acute wound care, dermatological and gynecological applications.
Qool Therapeutics
Qool Therapeutics
Qool Therapeutics develops non-invasive temperature management therapies to induce therapeutic hypothermia.
Obalon Therapeutics
Obalon Therapeutics
Obalon Therapeutics offers gastric balloon technology that assists weight loss by inducing a feeling of fullness.
Respicardia
Respicardia
Respicardia develops implantable therapies to improve respiratory and cardiovascular health.
Founding Date
Founding Date
2014
Founding Date
2012
Founding Date
2005
Founding Date
2008
Founding Date
2006
Type
Type
Public
Type
Public
Type
Private
Type
Public
Type
Private
Tags
Locations
Locations
New York, US HQ
Locations
Frankfurt am Main, DE HQ
Epalinges, CH
Nyon, CH
Locations
Mountain View, US HQ
Locations
Carlsbad, US HQ
Locations
Hopkins, US HQ
Employees
Employees
1
Employees
1122% increase
Employees
N/A
Employees
346% decrease
Employees
731% increase
Valuation ($)
Valuation ($)
1.7 m
Valuation ($)
9.3 m
Valuation ($)
N/A
Valuation ($)
6.7 m
Valuation ($)
N/A
Twitter followers
Twitter followers
351
Twitter followers
32
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
N/A
Alexa Website Rank
Alexa Website Rank
N/A
Alexa Website Rank
N/A
Alexa Website Rank
279249
Alexa Website Rank
322350
Alexa Website Rank
314264

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
€328.1k (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$3.3m (FY, 2019)
Revenue (est.)
N/A
Cost of goods
Cost of goods
N/A
Cost of goods
€157.6k (FY, 2017)
Cost of goods
N/A
Cost of goods
$3m (FY, 2019)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
€170.5k (FY, 2017)
Gross profit
N/A
Gross profit
$350k (FY, 2019)
Gross profit
N/A
Net income
Net income
($436.8k) (FY, 2019)
Net income
€3.8m (FY, 2017)
Net income
N/A
Net income
($23.7m) (FY, 2019)
Net income
N/A

Funding

Latest funding round
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
$ 8m (almost 3 years ago)
Latest funding round
N/A
Latest funding round
$ 58.5m (almost 3 years ago)
Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 8.3m
Total funding raised
$ 20m
Total funding raised
$ 149.1m
For sources of this data, please see the company profile

View company profiles

Elanix Biotechnologies
HQ
Frankfurt am Main, DE
Employees
11↑ 22% increase

Elanix Biotechnologies develops and commercializes products for acute wound care, dermatological and gynecological applications.

View company
Qool Therapeutics
HQ
Mountain View, US

Qool Therapeutics develops non-invasive temperature management therapies to induce therapeutic hypothermia.

View company
Obalon Therapeutics
HQ
Carlsbad, US
Employees
34↓ 6% decrease

Obalon Therapeutics offers gastric balloon technology that assists weight loss by inducing a feeling of fullness.

View company
Respicardia
HQ
Hopkins, US
Employees
73↑ 1% increase

Respicardia develops implantable therapies to improve respiratory and cardiovascular health.

View company